Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Esperion Therapeutics' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.55) EPS.

A number of other brokerages also recently weighed in on ESPR. Needham & Company LLC cut their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of "Hold" and an average target price of $6.25.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock traded up $0.01 during mid-day trading on Tuesday, hitting $1.10. 2,518,664 shares of the stock were exchanged, compared to its average volume of 5,247,869. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94. The company has a 50-day simple moving average of $0.96 and a 200 day simple moving average of $1.63. The company has a market capitalization of $218.02 million, a P/E ratio of -1.37 and a beta of 0.67.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The business had revenue of $65.00 million for the quarter, compared to analysts' expectations of $54.97 million. Analysts predict that Esperion Therapeutics will post -0.29 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently modified their holdings of the business. Wasatch Advisors LP grew its stake in Esperion Therapeutics by 4.9% in the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock valued at $53,861,000 after buying an additional 1,136,245 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after acquiring an additional 16,100 shares during the period. Nuveen Asset Management LLC grew its position in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after purchasing an additional 1,020,243 shares in the last quarter. Nuveen LLC bought a new stake in shares of Esperion Therapeutics during the 1st quarter valued at $4,446,000. Finally, JPMorgan Chase & Co. lifted its holdings in Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.